Investors & Media Investor Relations Overview Press Releases Scientific Publications & Presentations Corporate Deck Events & Presentations Press Kit Corporate Governance Financial Info Stock Info Analyst Coverage Investor Resources Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases Mar 21, 2023 Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema Read More Events & Presentations More events are coming soon. Contact IR
Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases Mar 21, 2023 Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema Read More Events & Presentations More events are coming soon.
Mar 21, 2023 Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema Read More